Atai Life Sciences N.V. (ATAI) stock declined over -1.09% intraday to trade at $3.64 a share on NASDAQ. The stock opened with a gain of 1.39% at $3.61 and touched an intraday high of $3.68, falling -1.09% against the last close of $3.68. The stock went to a low of $3.5 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue20.38 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Atai Life Sciences N.V. (NASDAQ: ATAI) stock price is $3.64 as of the last check on Thursday, June 30. During the trading session, ATAI stock reached the peak price of $3.68 while $3.5 was the lowest point it dropped to.
The NASDAQ listed ATAI is part of Pharmaceuticals industry that operates in the broader Health Care sector. Atai Life Sciences N. V.
Mr. Roman Dahl
VP of Operations & Innovation
Mr. Colin Keeler
Mang. of Corp. Fin.
Ms. Camilla Dormer
VP of Communications
Mr. Florian Brand
Co-Founder, MD & CEO
ATAI stock traded closed the last session at $3.64, which is $-0.04 or -1.09% lower than its previous close of $3.68. ATAI's current trading price is 23.39% lower than its 52-week high of $20.45 where as its distance from 52-week low of 2.95% is -82.20%.
Number of ATAI employees currently stands at -. ATAI operates from Krausenstrasse 9-10, Berlin 10117, Germany.
Official Webiste of $ATAI is: https://www.atai.life
ATAI stock volume for the day was 430,494 shares while in the previous session number of ATAI shares traded was 429,924 . The average number of ATAI shares traded daily for last 3 months was 842.44 Thousands.
The percentage change in ATAI stock occurred in the recent session was -1.09% while the dollar amount for the price change in ATAI stock was $-0.04.
In the recent session, the day high for ATAI stock was $3.68 while the low for ATAI stock touched on the day was $3.5.
The market value of ATAI currently stands at 563.47 Million with its latest stock price at $3.64 and 153.53 Million of its shares outstanding.